RA Capital Management
RA Capital Management is a crossover investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization.
TPG Biotech is TPG’s life science venture capital platform. With $1.2 billion in assets under management, TPG Biotech focuses on subsectors such as therapeutics, medical devices, and healthcare services. TPG’s team, which includes experienced investors, physicians, scientists, and technical experts, partners with innovative companies and talented entrepreneurs to expand and create new businesses. Since 2002, TPG Biotech has invested in more than 50 life science businesses.
Shin Nippon Biomedical Laboratories, Ltd.
Headquartered in Tokyo, Japan, SNBL is a leading global preclinical and early-stage clinical contract research services provider and creator of innovative therapeutic technologies, including the proprietary dry-powder nasal formulation and drug delivery device technologies incorporated in Satsuma’s lead product candidate, STS101, and the stereopure nucleic acid therapeutic technology being developed by SNBL spinout company, WAVE Life Sciences (NASDAQ:WVE).
Osage University Partners
OUP (Osage University Partners) is a venture capital firm focused on investing in startups that are commercializing pioneering university technologies. OUP partners with top research universities to invest in their most innovative startups, and OUP shares its investment profit with its partner institutions. The firm invests in software, hardware, and life science companies at all stages of company development. OUP has partnered with over 100 universities, including 41 of the top 50 U.S. institutions by research expenditures, and has invested in over 90 of their spinouts. OUP is part of a family of investment funds within Osage Partners, which is based in Philadelphia, PA and manages in excess of $800 million. For more information, visit www.oup.vc.
CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. CAM Capital manages assets exclusively for entities related to Mr. Kovner and its senior employees. CAM Capital’s goal is to achieve long-term compounded growth of its portfolio using a diversified, opportunistic investment strategy. In pursuit of this goal, CAM Capital engages in both trading activities and fundamentally driven investments. Our investments span all parts of the corporate capital structure in both the private and public markets.
Eventide Asset Management, LLC
Cormorant Asset Management
Cormorant Asset Management, is Boston based investment manager investing in publicly traded and privately held biotech companies. Bihua Chen is founder and portfolio manager of Cormorant Asset Management.
SBI Investment operates the core business in the Asset Management Business of the SBI Group, and is responsible for the operation and management of venture capital funds under the management philosophy to become the leading company in the creation and incubation of core industries of the 21st century as a “new industry creator”. The main fields of investment are growing fields including IT, bio/life science, environment/energy, and currently expanding into the Fintech, Ai and Blockchain fields.